BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T132422
CREATED:20200722T114844Z
LAST-MODIFIED:20200722T114844Z
UID:26443-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:3rd Annual Lab Asset & Facility Management in Pharma 2020
DESCRIPTION:The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM\, enabling you to regain control of your assets\, optimize your space and benchmark best practices to stay ahead of the curve. \n \nThrough strategic planning and rolling out digital tracking\, Lab Asset\, Operations and FM Directors are beginning to regain control of their inventory\, asset value and optimize facility footprint to: \n\nReduce unnecessary downtime and ensure reliable business operations\nStrengthen relationships and drive innovative partnership models with OEMs\nMaximize asset lifecycle and value – and make informed financial decisions during purchasing\, renewing\, reselling and auctioning\nOptimize lab and working space\, implementing the ethos of shared economy within the R&D scientific community\nEnhance capital efficiency to re-invest in drug development programs\nAnticipate expansion from a lab and equipment perspective
URL:https://www.pharmajournalist.com/event/3rd-annual-lab-asset-facility-management-in-pharma-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T132422
CREATED:20200727T160850Z
LAST-MODIFIED:20200727T160850Z
UID:26517-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:Digital Neuropsychiatric Drug Development Summit
DESCRIPTION:The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive\, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics. \n \nWith an emphasis on depressive disorders\, schizophrenia\, addiction and PTSD\, this timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nDive into novel therapeutic approaches for PTSD with Aptinyx\, Bionomics\, Tonix & MAPS\nUncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics\, NeuroRx & Intra-cellular Therapeutics\nExplore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis\, Otsuka & Yale University\nHear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA\nLearn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern\n\nUniting 60+ drug developers from all corners of the world\, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics. \nTo know more about Digital Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/digital-neuropsychiatric-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201114
DTSTAMP:20260515T132422
CREATED:20200818T085642Z
LAST-MODIFIED:20200818T090545Z
UID:26793-1604966400-1605311999@www.pharmajournalist.com
SUMMARY:TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:Europe’s #1 forum for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market\, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies\, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition\, and work towards collaborations.
URL:https://www.pharmajournalist.com/event/tides-europe-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201112
DTSTAMP:20260515T132422
CREATED:20201109T092141Z
LAST-MODIFIED:20201109T092440Z
UID:27850-1604966400-1605139199@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin 2020
DESCRIPTION:2019 proved to be a pivotal year for the skin microbiome\, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly\, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations. \n \nMoving forward into 2021\, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis\, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products. \nSo\, what’s different at Microbiome Connect: Skin EU Virtual? \nSix new topics to explore: \n\nThe skin-gut axis and the development of ingestible beauty products.\nPersonalisation of skin-microbiome products and formulation considerations.\nDefining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.\nNext generation sequencing techniques and their application in claims development.\nNew data demonstrating the role of the microbiome in common skin conditions including acne\, eczema and dandruff.\nThe vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.\n\nAll tickets to tune into this event are 2FOR1 – simply quote this when booking online!
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201111
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T132422
CREATED:20200908T143929Z
LAST-MODIFIED:20200908T143929Z
UID:26962-1605052800-1605225599@www.pharmajournalist.com
SUMMARY:2nd Digital Exosome Based Therapeutic Development Summit
DESCRIPTION:The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However\, more is needed to be done to uncover more scientific knowledge\, fine-tune manufacturing methods and prepare trials to meet regulatory expectations. \nConsidering this\, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12\, 2020) will unite pharma\, biotech\, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality. \n \nThis is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field\, it’s two days not to be missed. \nWith 20+ speakers and 2 days of unrivalled in-depth content\, join your peers to discuss: \n\nEnd-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes\, clinical preparation\, commercial strategy and more with Evox Therapeutics\, Aruna Bio\, Codiak Biosciences and ReNeuron\nInnovations in exosome-based therapeutics\, such as their applications in COVID-19 vaccines with Capricor Therapeutics\nUnderstanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen\nPreparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics\nOver 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!\n\nIf you are exploring the therapeutic applications of exosomes in an evidence-based approach\, this is the place for you. \nSpanning 2 days\, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery\, manufacturing\, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods\, consistent exosome production\, improved isolation and purification\, effective clinical and regulatory preparations\, beneficial industry partnerships and more. \nTo know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-digital-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR